Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2002 Nov;61(11):960-7.
doi: 10.1136/ard.61.11.960.

Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases

D S Hallegua  1 , M H Weisman
Affiliations
Review

Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases

D S Hallegua et al. Ann Rheum Dis. 2002 Nov.

Abstract

Objective: To review publications relating to the blocking of interleukin 1 (IL1) as a strategy for treating human disease, ranging from rheumatoid arthritis (RA) to Alzheimer's disease.

Methods: The National Library of Medicine's PubMed database was searched for articles about pharmaceutical agents that reduce the biological actions of IL1.

Results: Fish oils and corticosteroids were identified as non-selective pharmacological interventions that reduce the activity of IL1, whereas a recombinant human IL1 receptor antagonist (anakinra) and a soluble recombinant type I IL1 receptor act selectively. To date, anakinra is the only selective intervention that has been shown in controlled clinical trials to be effective and well tolerated in the treatment of a specific human disorder, RA. In controlled clinical trials, anakinra provided significant clinical improvement and slowed radiographic disease progression in patients with active RA. Moreover, addition of anakinra to existing methotrexate treatment significantly reduced signs and symptoms of active disease.

Conclusions: The clinical use of anakinra has been demonstrated in the management of RA, but blocking of IL1 in other human disorders, as well as the safety of the use of these blocking agents in chronic diseases, still needs to be defined by controlled clinical investigations.

PubMed Disclaimer

Figures

Figure 1
Figure 1
IL1Ra blocks IL1 binding and subsequent intracellular signalling.
Figure 2
Figure 2
Effect of IL1Ra on radiographic progression of RA. Serial hand radiographs at baseline and after 24 weeks were evaluated by the Genant method for patients treated with placebo (n=78) or IL1Ra 30 mg (n=86), 75 mg (n=83), or 150 mg (n=79). Statistical significance versus placebo is shown above each histogram. From Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000;43:1001–9. Copyright © 2000 Wiley-Liss Inc. Reprinted by permission of Wiley-Liss, Inc, a subsidiary of John Wiley & Sons, Inc.
Figure 3
Figure 3
Effect of combination IL1Ra and methotrexate treatment versus methotrexate alone on ACR 20% response rates after 24 weeks of treatment. From Cohen S, Hurd E, Cush JJ, et al. Treatment with interleukin-1 receptor antagonist in combination with methotrexate (MTX) in rheumatoid arthritis (RA) patients [abstract]. Arthritis Rheum 1999;42(suppl):S273. Copyright © 1994 Wiley-Liss Inc. Reprinted by permission of Wiley-Liss, Inc, a subsidiary of John Wiley & Sons, Inc.
Figure 4
Figure 4
Distribution of withdrawals due to adverse events with IL1Ra and placebo in patients with RA. From Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196–204. Copyright © 1998 Wiley-Liss Inc. Reprinted by permission of Wiley-Liss, Inc, a subsidiary of John Wiley & Sons, Inc.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Exp Med. 1994 Feb 1;179(2):739-43 - PubMed
    1. J Immunol. 1987 May 1;138(9):2857-63 - PubMed
    1. Crit Care Med. 1994 Jan;22(1):12-21 - PubMed
    1. JAMA. 1994 Jun 15;271(23):1836-43 - PubMed
    1. J Clin Invest. 1994 Jul;94(1):449-53 - PubMed

Publication types

MeSH terms